Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novocell, a stem cell engineering company, has entered into a non-exclusive drug discovery collaboration with Pfizer giving Pfizer access to Novocell's proprietary pancreatic progenitor cells derived from human embryonic stem cells.
Subscribe to our email newsletter
Under the terms of the agreement, Novocell will receive an upfront payment with additional amounts payable upon the achievement of certain technical milestones, as well as research funding.
In addition, Novocell will receive payments relating to the sale by Pfizer of any exclusive therapeutic discovered as a result of the collaboration. The duration of the research collaboration will be two years with the option by Pfizer to extend.
Alan Lewis, president and CEO of Novocell, said: “We are very pleased to collaborate with Pfizer, an industry leading pharmaceutical company with a strategic vision about regenerative medicine. This joint opportunity takes advantage of our leading stem cell engineering technologies and Pfizer’s expertise in drug discovery, providing for innovative, regenerative therapeutics.”